Imaging Diagnostic Systems Stock Rebound Continues (IMDS)

Imagining Diagnostic Systems (OTC: IMDS) rose to a solid 11.8% to a share price of $0.0019, continuing its respectable rebound. The stock has gained 280% in share price in five days, and 533% in one month. Volume of the stock stayed at well above its average.

Believe it or not, despite its recent huge rally, the year-to-date loss for Imagining Diagnostic Systems still totals 40.6%. The stock had been steadily tanking since the start of 2012 without any signs of rebound until recently. On January 4, 2012, a share of Imagining Diagnostic Systems was priced at $0.003.

Several newsletters have promoted Imagining Diagnostic Systems. For example, OTC Advisors promoted Imagining Diagnostic Systems twice last year and was compensated $5,000 each time. There are 16 results found on stockpromoters.com regarding to the stock promotion of Imagining Diagnostic Systems, which may include duplicate entries of stock promoting companies.

According to @pennystock24 on Twitter, Stock Blaster and Penny Stock Wizards promoted Imagining Diagnostic Systems today.

Imagining Diagnostic Systems hasn’t issued many press releases recently, aside from some Edgar filings. Here are a couple of headlines for the company dated back to May that are worth looking at:

  • May 22, 2012: Imagining Diagnostic Systems announced that it had signed a distribution agreement with Mareen Group to market and sell its Computed Tomography Laser Mammography (CTLM®) System in Kuwait.
  • May 14, 2012: Imagining Diagnostic Systems announced that it had signed a distribution agreement with Shimadzu Medical to market and sell its Computed Tomography Laser Mammography (CTLM®) System in Australia, New Zealand and the Pacific Islands.

Imaging Diagnostic Systems is a development stage medical technology company. The company is engaged in the development and testing of a Computed Tomography Laser Breast Imaging System for detecting breast cancer.

As of June 30, 2010, Imagining Diagnostic Systems was in the process of commercializing the CTLM in certain international markets where approvals to market have been secured, although CTLM is not yet approved for sale in the United States. During the fiscal year ended June 30, 2010, the company had no revenues from its operations.

The CTLM system is a CT-like scanner, but its energy source is a laser beam and not ionizing x-radiation such as is used in conventional x-ray mammography or CT scanners. CTLM is a new imaging modality offering the potential of functional molecular imaging, which can visualize the process of angiogenesis, which may be used to distinguish between benign and malignant tissue.

Imagining Diagnostic Systems’ Laser Imager for Lab Animals program is an optical helical micro-CT scanner in a third-generation configuration. The system was designed to image numerous compounds, especially green fluorescent protein, derived from the deoxyribonucleic acid of jellyfish.

The LILA scanner is targeted at pharmaceutical developers and researchers who monitor cancer growth and who use multimodality small animal imaging in their clinical research.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Fiona Gibson

Fiona is a finance graduate and an expert in analyzing market trends.

Recent Stories

SignUp Now For Our Featured Newsletter